$846.40 million U.S. Anti-nuclear Antibody (ANA) Testing Industry Analysis by 2025| Overview by Product, Technique, Disease, Symptoms and Top Venders- Alere

Pune India - June 26, 2018 /MarketersMEDIA/ —

U.S. Antinuclear Antibody Test Market Overview by Product (Reagents & Assay Kits, Systems, Software & Services), By Technique (ELISA, Immunofluorescence Assay, Multiplex Assay), By Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Scleroderma), By End User (Hospitals, Clinical Laboratories, Physician Office Laboratories), By Country – Industry Trends and Forecast to 2025

Avail 10% instant discount on this report mail us at sopan.gedam@databridgemarketresearch.com

U.S. Anti-nuclear Antibody Test Market will reach USD 846.40 million by 2025 from USD 473.10 million in 2017 with a CAGR of 7.6% in the forecast period of 2018 to 2025.

Click here for Free Sample Report with Discount on Full Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=u-s-antinuclear-antibody-test-market

Covered in this report

The report covers the present scenario and the growth prospects of the U.S. anti-nuclear antibody test market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

The key market players for U.S. anti-nuclear antibody test market are listed below:

• Bio-Rad Laboratories, Inc.
• Alere, Inc.
• Trinity Biotech
• Thermo Fisher Scientific Inc.
• Antibodies Inc.
• EUROIMMUN AG
• Immuno Concepts

Any specific requirements are you looking for? Ask to your Industry Experts @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-transradial-access-market

The market is further segmented into:
• Product
• Test
• Disease
• End-user

The U.S. anti-nuclear antibody test market is segmented on the basis of product, test, disease and end-user. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.
The U.S. anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the U.S. anti-nuclear antibody test market with 50.2% market share and is expected to reach USD 432.80 million by 2025, with the highest CAGR of 7.9% in the forecast period 2018 to 2025.

The U.S. anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, Indirect Immunofluorescence is expected to dominate the U.S. anti-nuclear antibody test market with 44.0% market share and is expected to reach USD 347.13 million by 2025, with the CAGR of 6.6% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 8.9% in the forecast period, and is expected to reach USD 217.89 million in 2025 from USD 110.70 million in 2017.

The U.S. anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, Systemic Lupus Erythematosus is expected to dominate the U.S. anti-nuclear antibody test market with 26.2% market share and is expected to reach USD 239.47 million by 2025, at the highest CAGR of 8.8% in the forecast period 2018 to 2025.

The U.S. anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the U.S. anti-nuclear antibody test market with 45.9% market share and is expected to reach USD 396.88 million by 2025, at the highest CAGR of 8.0% in the forecast period 2018 to 2025.

Read more about U.S. Anti-nuclear Antibody Test Market Report Visit @ http://databridgemarketresearch.com/reports/u-s-antinuclear-antibody-test-market/

TABLE OF CONTENTS

1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. YEARS CONSIDERED FOR THE STUDY
2.3. CURRENCY AND PRICING
2.4. RESEARCH METHODOLOGY
2.5. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6. SECONDARY SOURCES
2.7. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
3.1.2. RISING MEDICAL INSURANCE
3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION
3.2. RESTRAINTS
3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL
3.3. OPPORTUNITIES
3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
3.3.2. LABORATORY AUTOMATION FAVORS THE MARKET
3.4. CHALLENGES
3.4.1. LACK OF SKILLED PROFESSIONALS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT
6.1. OVERVIEW
6.2. ASSAY KITS & REAGENTS
6.3. SYSTEMS
6.4. SOFTWARE
7. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST
7.1. OVERVIEW
7.2. INDIRECT IMMUNOFLUORESCENCE
7.3. ELISA
7.4. MULTIPLEX TESTING
8. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE
8.1. OVERVIEW
8.2. RHEUMATOID ARTHRITIS
8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
8.4. SJÖGREN’S SYNDROME
8.5. SCLERODERMA
8.6. POLYMYOSITIS
8.7. OTHERS
9. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER
9.1. OVERVIEW
9.2. HOSPITALS
9.3. CLINICS
9.4. PHYSICIAN OFFICE LABORATORIES
9.5. OTHERS
10. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, COMPANY LANDSCAPE
10.1. COMPANY SHARE ANALYSIS: NORTH AMERICA
11. COMPANY PROFILES
11.1. THERMO FISHER SCIENTIFIC INC.
11.2. MERCK KGAA
11.3. ALERE INC.
11.4. TRINITY BIOTECH
11.5. ANTIBODIES INC.
11.6. BIO-RAD LABORATORIES, INC.
11.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)
11.8. IMMUNO CONCEPTS
11.9. INOVA DIAGNOSTICS
11.10. ZEUS SCIENTIFIC, INC.
11.11. MBL INTERNATIONAL
11.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD
11.13. AESKU GROUP GMBH & CO. KG
12. RELATED REPORTS

Browse Detailed TOC, Tables and Figures @ http://databridgemarketresearch.com/toc/?dbmr=u-s-antinuclear-antibody-test-market

Contact Info:
Name: Sopan Gedam
Email: Send Email
Organization: Data Bridge Market Research
Phone: +1-888-387-2818
Website: https://databridgemarketresearch.com/reports/u-s-antinuclear-antibody-test-market/

Release ID: 365414